<DOC>
	<DOCNO>NCT02629861</DOCNO>
	<brief_summary>The study conduct evaluate two dos TEV-48125 adult patient episodic migraine</brief_summary>
	<brief_title>Efficacy Safety 2 Dose Regimens TEV-48125 Versus Placebo Preventive Treatment Episodic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Males female age 18 70 year , inclusive , migraine onset â‰¤50 year age Patient sign date inform consent document Patient history migraine accord International Classification Headache Disorders , clinical judgment suggest migraine diagnosis 85 % ediary compliance Total body weight 99 265 lb , inclusive Additional criterion apply , please contact investigator information Clinically significant hematological , cardiac , renal , endocrine , pulmonary , gastrointestinal , genitourinary , neurologic , hepatic , ocular disease , discretion investigator Evidence medical history clinically significant psychiatric issue , include suicide attempt past , suicidal ideation specific plan past 2 year History clinically significant cardiovascular disease vascular ischemia ( myocardial , neurological [ eg , cerebral ischemia ] , peripheral extremity ischemia , ischemic event ) thromboembolic event ( arterial venous thrombotic embolic event ) , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , pulmonary embolism Known infection history human immunodeficiency virus , tuberculosis , chronic hepatitis B C infection Past current history cancer last 5 year , except appropriately treat nonmelanoma skin carcinoma Pregnant nursing female History hypersensitivity reaction inject protein , include monoclonal antibody Participation clinical study new chemical entity prescription medicine within 2 month 5 halflives , whichever longer Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>